ArticleEuropean journal of nuclear medicine and molecular imaging2019
Hybrid PET/MRI in major cancers: a scoping review.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Diagnostic performance of whole-body [European radiology · 2024Pooled it
- Staging of Cervical Cancer: A Practical Approach Using MRI and FDG PET.AJR. American journal of roentgenology · 2023Review
- PET/MR versus PET/CT for locoregional staging of oropharyngeal squamous cell cancer.Acta radiologica (Stockholm, Sweden : 1987) · 2023Article
- Direct reconstruction for simultaneous dual-tracer PET imaging based on multi-task learning.EJNMMI research · 2023Article
- Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer.Cancers · 2022Article
- Optimization of whole-body 2-[European radiology · 2022Article
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.International journal of molecular sciences · 2022Review
- A decade of multi-modality PET and MR imaging in abdominal oncology.The British journal of radiology · 2021Review
- Value of integrated PET-IVIM MRI in predicting lymphovascular space invasion in cervical cancer without lymphatic metastasis.European journal of nuclear medicine and molecular imaging · 2021Article
- Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review.European journal of nuclear medicine and molecular imaging · 2021Review
- Diagnostic Value ofDiagnostics (Basel, Switzerland) · 2021Article
- Diagnostic efficiency of whole-bodyCancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.Annals of nuclear medicine · 2020Review
- IsEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Diagnostic value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Diagnostic value of [EJNMMI research · 2020Article
- Distant metastases and synchronous malignancies on FDG-PET/CT in patients with head and neck cancer: a retrospective study.Acta radiologica (Stockholm, Sweden : 1987) · 2020Article
- Metastatic disease in head & neck oncology.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePET/MRI was introduced for clinical use in 2011 and is now an established modality for the imaging of brain and certain pelvic cancers, whereas clinical use for the imaging of other forms of cancer is not yet widespread. We therefore systematically investigated what has been published on the use of PET/MRI compared to PET/CT in the imaging of cancers outside the brain, focusing on clinical areas of application related to diagnosis, staging and restaging.
methodsA systematic search of PubMed/MEDLINE, Embase and the Cochrane Library was performed. Studies evaluating the diagnostic performance of simultaneous PET/MRI in cancer patients were chosen.
resultsA total of 3,138 publications were identified and 116 published during the period 2012-2018 were included and were grouped according to the major cancer forms: 13 head and neck (HNC), 9 breast (BC), 21 prostate (PC), 14 gynaecological, 13 gastrointestinal (GIC), and 46 various cancers. Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of
conclusionThe scoping review methodology resulted in the identification of a huge number of records, of which less than 5% were suitable for inclusion and only a limited number allowed conclusions on the advantages/disadvantages of PET/MRI compared to PET/CT in the oncological setting. There was evidence to support the use of FDG PET/MRI in staging of nasopharyngeal cancer and high-risk BC. Preliminary data indicate the superiority of PET/MRI for the detection of local recurrence in PC, local tumour invasion in cervical cancer, and liver metastases in colorectal cancer. These conclusions are based on small datasets and need to be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.